Developing bacterial immunotherapies for oncology and infectious diseases. Microviable Therapeutics is a biotech company at pre-clinical stage, developing novel bacterial immunotherapies for oncology and AMR infectious diseases. Microviable was incorporated in 2016, as a spinoff of the Spanish National Research Council (CSIC). Microviable has received the European Seal of Excellence two times, a growing IP portfolio and numerous national and regional awards, and the certificate of Innovative SME. www.microviable.com Intestinal Microbiota, Intestinal disease, Clostridium difficile, Biotechnology, Microbiology, microbiota, microbiome, gut microbiota, gut health, probiotics, microbiota storage, microbiota isolation, GutAlive, anaerobes, human purified microbiota , biotherapeutics, and LBPs

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reporting on the latest Microbiome Scientific & Business Developments With over 100 trillion bacteria and other microbes estimated to inhibit the human body alone, we are seeing new knowledge and applications of microbiomes develop at an alarming rate, bringing with it new licensing agreements, large investments, IPOs, strategic partnerships and acquisitions across the Pharma and Human Health, Animal Health and Agriculture industries. Microbiome TimesTM aims to assist science entrepreneurs to acquire insights that will expand the envelope of applied microbiome knowledge and offers a one-stop-shop to stay up to date with this fast paced industry. Pharmaceuticals, Human Health, Microbiome, Probiotics, …

60 similar entities Type: Startup Activities: deeptech biotech healthtech

Pioneering rational design of drugs made of defined bacteria consortia that are essential dwellers of the gut ecosystem. The trillions of microbes that call us home –the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Siolta Therapeutics is a clinical-stage biotech company developing live biotherapeutics to improve outcomes in conditions with unmet medical needs. Our offices and laboratory are located in San Carlos, CA. Microbial Therapeutics, Host Microbe Interactions, Human Microbiome, and Pharmaceutical Development

271 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the microbiome for the development of diagnosis and therapeutic tools in cancer ! EverImmune is a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology. It harnesses the gut microbiota for the development of a unique approach aiming to restore the response of Immune Checkpoint Inhibitors (ICIs) in cancer patients. The company is developing Oncobax AK, a Live Biotherapeutic Product (LBP) used as an oral adjuvant to anticancer immunotherapies, designed to safely boost the immune system and restore sensitivity to immunotherapies in primary resistance settings. The company also develops other bacteria in …

123 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unibiome develops fermentative microbes that have been engineered to produce vitamins and other healthy compounds and designed to be used with any fermentation-based food to increase its nutritional value. We believe that re-purposing the food microbiome is a game-changing approach to feeding 9 billion people by 2050. Biotechnology, Synthetic Biology, Design, Microbiology, and Food Fortification

106 similar entities Type: Startup Activities: biotech foodtech Technologies: Synthetic Biology

Innovation, precision, and purpose - redefining infection diagnostics for better outcomes. At Noscendo, we save and improve lives by revolutionising infection diagnostics. Through our metagenomic technology DISQVER®, we empower clinicians to identify pathogens rapidly, precisely, and without assumptions — helping patients receive the right treatment at the right time. We believe in a future where infectious diseases no longer claim lives unnecessarily. Driven by our values, we act with openness and reliability, always put patients first, grow and empower each other, and innovate to elevate modern medicine. We take ownership — and deliver results that matter.

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing cancer care through microbiome profiling 🦠 Discover your microbiome: www.mybioma.com Biome Diagnostics GmbH (BiomeDx®) is an Austria-based MedTech company driving precision medicine through pioneering microbiome-based technologies that transform cancer care. At the intersection of state-of-the-art DNA sequencing and advanced machine learning, BiomeDx® develops first-in-class solutions for routine clinical practice. In addition to the lifestyle product myBioma (www.mybioma.com) for end-customers, the company focuses on medically certified products in the fields of gut microbiome and cancer. With ISO 9001 and ISO 13485 certifications, BiomeDx® is the first microbiome company worldwide with dual ISO certification — reflecting our commitment to safety and …

79 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology A.I. A.I. - Machine Learning

Eveliqure Biotechnologies is developing novel vaccines for the prevention of diarrhoeal diseases. Eveliqure Biotechnologies is an innovative biotech company developing novel vaccines for the prevention of diarrhoeal diseases both for travellers and people living in endemic regions of low- and middle-income countries. Eveliqure is a game-changer amongst vaccine companies, championing novel technologies to make the world safe from diarrhoea. Eveliqure is passionate about improving the quality of life for both the poor and the privileged by providing innovative medical solutions that fight diarrhoeal diseases.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Microbiology assays at previously impossible speeds and strain banks with amazing diversity ! Microbiology is what we do. Our unrelenting focus has enabled us to develop unique capabilities in ultra-high-throughput single-cell culture of microorganisms. Businesses in areas as diverse as pharma, agriculture, food, human health and environmental protection have partnered with us to gain powerful competitive advantages from our technology.So could yours. Our proprietary microfluidic platform is capable of : - identifying microbes of interest based on their functional characteristics among millions of candidates - perform a wide range of assays at previously impossible speeds - generate strain banks with …

144 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Diotheris develops anti-infective microbes to prevent bacterial infections and act against antibiotic resistance We create bacterial therapies of the human skin and mucosal microbiome against pathogenic bacteria. Our first suite of products (NASOFLORE line) targets Staphyloccocus aureus / MRSA (Methicillin resistant S aureus). The products based on live bacteria identified in our clinical and in vitro studies do not generate emergence of antibiotic resistance. antimicrobial, nose microbiome, therapeutics, LBP, Staphylococcus Aureus, and MRSA

71 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

A Microbiota biotherapeutics and Vaccines company. Conditioning the gut ecosystem for disease prevention and therapy. Spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland, aimed at shaping the intestinal microbiota for the cure and prevention of diseases such as bowel diseases and cancer. The gut ecosystem conditions the function of all our organs and plays a fundamental role in our wellbeing. The mucosal immune system has co-evolved with the intestinal microbiota to adapt its function to a number of environmental and possibly pathogenic factors. MV Bio leverages a microbiota-mediated mechanism regulating the physiological response of the intestinal …

55 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Restore health and save lives through innovative medicines Rostra strives urgently to bring novel medicines to patients and clinicians with the power to restore health and save lives globally. Through its novel technology platform, Rostra is developing medicines for infectious diseases with an initial focus on invasive fungal infections. Pharmaceutical Discovery & Drug Development and Infectious Disease

85 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Leading the Microbiome revolution Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWSTTM, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in …

137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

RESEARCH AND INNOVATION TO GROW TOGETHER Smartfarma was born to help parents and doctors raise healthy and strong children. We constantly invest in research to offer better products to provide the correct vitamin intake and to strengthen the immune system of newborns, children and new mothers. We believe in innovation with high added value, which is why we are pioneers in the use of postbiotics in the neonatal field, extraordinarily effective excipients in strengthening the immune defenses. Scientific research is one of our distinctive elements. We are the first and only company in Italy to have a line of products …

41 similar entities Type: Startup Activities: deeptech

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

267 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Superior and effective microbiome therapeutics CHAIN Biotechnology was founded in 2014, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome. CHAIN has built an impressive technical team of molecular biology, microbiology, microbiome and fermentation specialists focused on the biotechnology development of Clostridia. In addition, CHAIN leverages synthetic biology expertise from the Synthetic Biology Research Centre at the University of Nottingham. CHAIN has developed a proprietary microbial platform for drug delivery. The platform builds on core engineering skills and involves the development and use of engineered Clostridia to deliver specific …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Translating Complex Microbiome Data into Actionable Healthcare Insights DATABIOMIX is a Swiss techbio company turning the human gut microbiome into a digital twin through an AI foundational model to leverage science-based dietary recommendations. We deliver this intelligence across three offerings: 1. Nutrition & Lifestyle We empower nutritionists, health coaches, and preventive-care practitioners with AI-driven microbiome insights that translate complex microbiota profiles into gut health assessments. 2. Research Testing We accelerate the discovery journey of research teams in SMEs and biotech labs with our microbiota biomarker discovery, characterization, and tracking solutions. 3. Pharma and Biotech We build gut microbiome digital twins …

67 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: A.I. A.I. - Machine Learning

We accompany companies with a complete service of Preclinical Trials and Clinical Trials of safety and efficacy GOYA INNOVA is a Spanish laboratory with 50 years of experience, specialized in preclinical and clinical evaluations of safety and efficacy for cosmetic, health products and food supplements.⁣ We manage 55,000 samples annually, and with our partners, we offer a comprehensive service.⁣ Our differential model of preclinical and clinical research integrates a CRO with its own Medical and Medical-Aesthetic Center.⁣ With more than 40 doctors of different specialties, we can:⁣ • Carry out studies under the highest quality standards⁣ • Optimize costs and …

289 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Clinically proven probiotics for the benefit of human health throughout life. Products available B2C & B2B worldwide. BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 35 years. BioGaia develops, manufactures, markets, and sells probiotic products within the areas of gut health, oral health, and immune health. Our probiotic products with bacterial strains from the L. reuteri species are among the most scientifically well-documented probiotics. BioGaia`s products are distributed through own subsidiaries or distribution partners in more than 100 countries.The class B share of BioGaia is quoted on the Mid Cap …

44 similar entities Type: SMB Activities: healthtech deeptech

Redefining microbiome-based therapeutics MRM Health NV is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.The company is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent, Belgium, and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB and has a corporate collaboration with DuPont Nutrition …

129 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche …

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vital new drugs for pandemic infections We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections. Pharmaceuticals, R&D, Antimicrobial Resistance, and Development

147 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and act without personal liability. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections …

236 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

We invent for life! At MSD - known as Merck & Co., Inc. in the United States and Canada, headquartered in Rahway, New Jersey - we are united by our purpose of harnessing the potential of science to save and improve lives around the world. For more than 130 years, we have provided hope through the development of important medicines and vaccines. We aspire to be the world's leading biopharmaceutical research company and are currently at the forefront of research into innovative health solutions to advance the prevention and treatment of human and animal diseases. We foster a diverse and …

237 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The world's go-to partners for infectious disease biomaterials and testing services. We are the world’s leading experts and go-to collaborators in biological products and services, focused on protecting the health and safety of people around the world. For over 50 years, we have been partnering with healthcare and life science laboratories, manufacturers and suppliers across the globe to co-create and provide biological control materials, assay services and consulting for microbiology, molecular diagnostics and virology. Headquartered in Saint Cloud, Minnesota, we have additional facilities in California, Kentucky and Michigan. Microbiology, Biotechnology, Quality Control, Molecular Microbiology, Contract Research Organization, Virology, Anti-Infective Drug …

207 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Leadership in overcoming the antibiotic resistance crisis. BioVersys AG is a SIX listed (BIOV) clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company’s two in house technology platforms: i) TRIC and ii)Ansamycin chemistry, BioVersys develops novel, innovative antibacterial drugs, overcoming resistance and modulating the microbiome. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Enhancing digestive health GoodGut is a biotechnology company focused on researching and developing analysis systems and therapeutic products to improve the diagnosis and treatment of digestive diseases based on intestinal microbiota. We aim to provide technological tools that will help to obtain a faster, more reliable and lower cost medical diagnosis than existing methods, alongside therapies to improve the quality of life of patients with compromised digestive health. The company was created in 2014 as a spin-off of the University of Girona (UdG) and the Institute of Biomedical Research of Girona Dr. Josep Trueta (IdIBGi). Our facilities can be found …

163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing Tomorrow's Antibacterials Antabio is a privately held, clinical-stage biopharmaceutical company dedicated to developing novel and highly differentiated antibacterial treatments targeting drug-resistant infections caused by WHO and CDC critical priority pathogens. Guided by scientific excellence and a clear mission, Antabio’s mission is to deliver life-saving therapies that combat antimicrobial resistance (AMR) and help preserve the effectiveness of antibiotics for future generations. Antabio’s lead program, MEM-ANT3310, is a next-generation β-lactam/β-lactamase inhibitor (BL/BLI) combination currently in Phase 1 clinical development. Designed to treat severe hospital infections caused by multidrug-resistant Gram-negative bacteria, MEM-ANT3310 represents a major step forward in addressing one of the …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading biotech in the development of innovative microbiome-based biotherapies YSOPIA Bioscience is a clinical-stage biotech company developing cutting-edge biotherapies based on the gut microbiome. Our goal is to bring safe & efficient solutions to patients with high unmet medical needs. Microbiome, Obesity, Gut modulator, Cardiometabolism, Cardiometabolic diseases, Microbiota, and Gut microbiota

298 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AI-Native Phage Therapy We are facing a global crisis where bacterial infections are becoming increasingly deadly due to antibiotic resistance. The health and economic consequences are staggering, with bacterial disease predicted to be the #1 cause of death by 2050. Alternatives are urgently needed, but nature already has its solution: phages, the natural predators of bacteria. At Phagos, we are bringing back phage technology by combining advances in microbiology with cutting-edge artificial intelligence. Our patented technology makes large-scale, customized phage-based veterinary medicines possible for the first time. And soon we'll universalize the technology for human health too. Our mission is …

65 similar entities Type: Startup Activities: biotech healthtech Technologies: Decarbonization

Empowering the Health Microbiome Movement The gut microbiome (i.e: the microorganisms present in our intestine) plays a major role in maintaining our health. In case of dysfunction, the microbiome is linked to a large number of inflammatory, metabolic, and neurological diseases. The study of the microbiome opens many perspectives for tomorrow’s medicine. Pelican Health offers a solution enabling multiple sampling of the microbiome in-situ with a single oral administration, in a reliable, precise, simple to administer and non-invasive manner.

47 similar entities Type: Startup Activities: deeptech

Therapeutic Innovations and Resistance INTHERES research revolves around the exploration of dose-exposure-effect relationships of antibiotics and internal and external antiparasitics. Their aim is to produce innovative solutions that lead to reduced and optimized use of anti-infectives. The work carried out within INTHERES is part of a “One-health” approach, at the interfaces of the Man-Animal-Environment triptych. INTHERES is a multidisciplinary unit, whose collective brings together skills in the fields of biology (microbiology, entomology, parasitology, cellular and molecular biology), analytical chemistry, pharmacology and mathematics. INTHERES welcomes university hospital staff (Faculty of Pharmacy), in conjunction with the Toulouse University Hospital. They are developing …

64 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Make Visible the Invisible Faster to Make your World Safer Founded in 2014, DIAMIDEX (Diagnostic Microbiology Express) is an innovative company specialized in the detection and quantification of microorganisms of interest. Its mission: making the invisible visible faster, to make your world safer. Its patented innovative technological approach brings about a major breakthrough to meet the speed and technicality challenges arising from microbiological culture. Based on a powerful technological platform, recognized by the scientific and industrial communities, DIAMIDEX offers and develops turnkey test solutions, which can be used in both laboratories and in the field to obtain a quantitative count …

136 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

goes FAR BEYOND (Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases) Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed. Dimicare Biotech is building a great team involving Microbiology Medical doctors, …

171 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Accelerate your innovation with your clinical and microbiome partner! A leading C.R.O specialised in designing and running of experimental, pre-clinical sample analysis and clinical research projects, with a unique nutrition and microbiome analytical service: • Internal Clinical Investigation Centers and Central Lab capabilities, • Management of local and multi-center projects, • Extensive experience with microbiota tool box and metagenomics services, from sample collection to analytical processes and biostatistics. BIOFORTIS GROUP With over 20 years of expertise, the Biofortis Group is an international CRO and consulting organization specialized in services dedicated to health and innovation. Built on three complementary entities - …

130 similar entities Type: SMB Activities: deeptech Technologies: SaaS

Make​ your Own Neuronal Network At MicroBrain Biotech, our mission is to revolutionize drug development by embracing ethical and cruelty-free practices, putting humanity at the center of our work, and relentlessly pursuing groundbreaking discoveries. We are committed to creating innovative solutions that improve the quality of life for patients and their families, while treating all living beings with compassion and respect. Through collaboration, scientific excellence, and a commitment to sustainability, we aim to leave a lasting positive impact on the world of healthcare and beyond.

143 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

THE FUTURE OF AGRICULTURE Nordic microbes is a Danish biotech company based in Odense. We develope natural, microbial products that can help farmers reduce their use of agrochemicals while maintaining or improving their yield. Our vision is to reduce the use of pesticides, antibiotics and synthetic fertilisers in agriculture to ensure a sustainable future. We have developed a unique approach and technology platform that enables us to rapidly discover new beneficial microorganisms. Visit our website and YouTube channel to learn more about our technology and our products. https://www.nordicmicrobes.com https://www.youtube.com/@nordicmicrobes microbiology, biologicals, microbial discovery, biofertilizer, biopesticides, crop protection, and crop fertilization

127 similar entities Type: Startup Activities: biotech Technologies: Bio sourced materials

Life-Transforming Medicines for Patients Living with Serious Rare Diseases VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. The company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in R&D, commercialization and …

146 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Precise Insights for Better Health Delivering on our promise to identify any microbe, from any sample, anywhere in the world will take a team of dedicated, passionate, and experienced individuals. The members of our team at IDbyDNA have a strong track record of building successful organizations and bring a breadth of multi-disciplinary experience including; microbial genomics, bioinformatics, software engineering, laboratory medicine, and commercialization. In concert with the global community of researchers, clinicians, industry partners and policy makers, we will revolutionize microbial detection and bring new solutions to solve problems that are not currently addressable with today’s technologies.

135 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: SaaS

Microbial solutions and microbiome skincare with live bacteria In Lactobio we focus on the creation of new microbiome and microbial solutions to target and fight the problem of increasing infections caused by microorganisms being resistant to antibiotics. We work with the skin, vaginal, and gut microbiota to treat a variety of diseases – with projects spanning various pathogens. Lactobio has obtained very promising clinical results, with isolated lactic acid bacteria having a significant antibacterial activity against Staphylococcus aureus, Methicillin Resistant Staphylococcus aureus (MRSA) and other pathogens.

55 similar entities Type: Startup Activities: deeptech biotech

Stellate Therapeutics develops innovative microbiome-derived small molecules to treat neurodegenerative diseases. Stellate Therapeutics is a pre-clinical stage start-up company developing innovative microbiome-derived small molecules to treat neurodegenerative diseases. We utilize the microbiome for our drug portfolio and our research focuses on the gut-brain axis. Due to millions of years of co-evolution, complex metabolic interactions exist between humans and their gut bacteria and Stellate has uncovered a unique set of metabolites that are produced by the microbiome and are involved in the maintenance of health. Our first drug will be a treatment for Parkinson’s disease.

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Trilliome, we're dedicated to enhancing healthspan and quality of life through groundbreaking, microbiome-targeting precision nutraceuticals. Our innovative, plant-derived supplements are scientifically formulated to optimize gut and brain health by promoting beneficial bacteria while suppressing harmful ones. With a robust foundation in research and an unwavering commitment to sustainability, our solutions address the global health crisis resulting from poor lifestyle choices. Led by seasoned industry professionals with PhDs and MBAs and with extensive experience in life sciences and microbiome research, Trilliome aims to transform the gut health market and empower individuals worldwide to achieve optimal longevity. Join us on this …

72 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Evolution. Adaptation. Future. Phage-based solutions to combat bacteria. - Prevention - Diagnosis - Treatment "One Health" personalized treatments. biotecnología, microbiología, investigación, biomedicina, bacteria, phage, and phage therapy

185 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Developing a novel antibiotic regimen with ability to act on a wide range of multi-drug resistant bacteria. Thioredoxin Systems AB is a biotechnology company developing a novel antibiotic regimen against pathogenic bacteria. EbsArgent is a patented combination of ebselen and silver, capable of functioning as an antiseptic, antibacterial in food production, and as a medicinal product. With its versatility and ability to act on a wide range of multi-drug resistant bacteria, it is among the most promising antibiotic regimen under development today.

68 similar entities Type: SMB Activities: biotech healthtech deeptech Technologies: Synthetic Biology

Enhancing global health through scientific food ingredients that fortify the gut microbiome We're on a mission to improve global gut health and help combat antimicrobial resistance. Bactolife is a Danish biosolutions company pioneering a new category of food ingredients: HelmTM Binding Proteins that selectively bind and block harmful microbial activity without disturbing the beneficial microbiome. Our binding proteins can be incorporated into foods, beverages, and dietary supplements. Backed by leading investors including Cross Border Impact Ventures, EIFO, Novo Holdings, and Athos, we're working to make HelmTM Binding Proteins a globally accessible solution for better gut health. Join us as we …

47 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

Founded in 1951 by pharmacists and microbiologists, biose® has 60-year experience in drug based on live bacteria, giving us a deep understanding of the entire process from discovery to commercialization. Focused on Health through microbiota and microbiome science, we use our skills for the discovery, product development, clinical studies and manufacturing of Live Biotherapeutic Products (LBPs). Our company is drug-GMP certified for the manufacturing of bacteria-based APIs, clinical and commercial products. Microbiome Therapeutics, live biotherapeutics, LBPs, and CDMO

127 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

From Microbes to One Health. Taylor made R&D to tackle infectious diseases. Vibiosphen is a SME healthcare biotechnology in infectious diseases founded in 2014. Given the important and interdependent human, animal, and environmental dimensions of antimicrobial resistance, the One Health concept promotes a global effort to achieve the best health for people, animals, and the environment. In this context, Vibiosphen takes part of the efforts that are underway to develop new anti-infective therapies, to rejuvenate the antibiotic pipeline, develop novel antibiotics, and discover innovative therapeutic strategies for priority pathogens. Based on its pluridisciplinary and integrated approaches, Vibiosphen, with more than …

63 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Molecular biology thought for your needs Biomnigene, a bioanalysis service company, helps prevent potential diseases and to authenticate, trace, secure, validate products and their effects through genetic analysis. Thanks to our expertise, we offer you integrated services for environmental, industrial (pharmaceutical, agro-food, cosmetic) or medical issues such as: - Analysis of the intestinal, skin, vaginal, pulmonary and soil microbiome (16S/ITS metagenomic, shotgun metagenomic, transcriptomic, WGS...). - Identification, quantification and authentication, monitoring of species in a pure sample and in a mixture (microorganisms, viruses, bacteria, meat, fish). - Genotyping - Antibody sequencing and safeguarding of hybridoma lines of special interest; - …

197 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Crossing the next frontier, to give you a fair chance to fight Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms. Inflammatory Bowel Diseases, Live Biotherapeutics, Microbiome, Immunotherapies, Immuno-oncology, and Immuno-inflammation

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

4Billion people suffer silently. We’re building the world’s first gentle, non-antibiotic cure for H. Pylori. Imagine a world where we no longer need antibiotics to treat one of the most common bacterial infections in humans. At Lant Medical, we’re pioneering Pylorin... a first-of-its-kind, non-antibiotic treatment for H. Pylori, the bacterium responsible for billions of gut infections globally and linked to gastric cancer, ulcers, and long-term digestive issues. Unlike antibiotics, which kill everything (good and bad), Pylorin works differently. It absorbs and removes the harmful bacteria... while protecting your gut’s natural ecosystem. We believe the future of medicine is gentle, precise, …

65 similar entities Type: SMB Activities: biotech healthtech deeptech

At the forefront of the fight against antibioresistant bacteria Pherecydes Pharma develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections in humans, particularly those resistant to antibiotics. Phages are natural predators of bacteria and have no demonstrated effect on eukaryotic cells, including human cells. Antimicrobial resistant bacteria or AMR are responsible for over 700,000 death a year in 2014 according to the WHO. This number might reach over 10,000,000 by 2050 if nothing is done, and no new class of antibiotics has been discovered in the last 30 years. Phages represent one of …

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives with personalised, accessible, adaptive phage therapy to help clinicians cure complex infections Our mission is to transform lives with personalised, accessible, adaptive phage therapy that cures difficult bacterial infections and restores hope for patients. To ensure every bacterial infection can be effectively treated and to restore hope for patients with no remaining options.

61 similar entities Type: Startup Activities: healthtech deeptech

From Probiotics to PreciBiomics TargEDys is a French commercial-stage biotech company specialized in the development of precision probiotics, or PreciBiomic solutions. Our mission is to detect, transpose and make available microbiome-based innovations to answer global public health challenges. How? By translating microbiome fundamental research from prestigious French institutes such as the Inserm and IGFL to applied research in probiotics, understanding the molecular mechanism of action of our strains, and developing industrial processes and IP to propose turnkey science-backed probiotics. Our vision is to bring the microbiome to the heart of healthcare and harvest its immense potential to improve the quality …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus. Anti-Infectives, Drug Discovery, Antibiotics, and Microbiology

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Characterizing the microbial and spoilage risk in meat and seafood products The unit's missions are to produce and disseminate knowledge and scientific methods in the field of microbiological food safety to respond to industrial challenges and societal demands for public health and control of food loss. Its research actions aim to characterize and control the microbial risk (health and spoilage) in meat and seafood products. Molecular, classical and predictive microbiology methods are used to understand, quantify and model the behavior of microorganisms during food processing, at the scale of the microbial ecosystem or at the scale of model species, in …

34 similar entities Type: Startup Activities: deeptech

For the benefit of patients Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in the heart of the life sciences hub of Basel area, Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands: Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. In addition, we have several preclinical anti-infective assets in our portfolio. Basilea currently has about 150 employees and is listed on the SIX Swiss Exchange (SIX: …

98 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

What life can do Abolis Biotechnologies is a French biotechnology company specializing in microbial systems and industrial-grade biotech applications for the food, cosmetics, healthcare and chemical industries. The company helps innovators, manufacturers and R&D teams understand complex microbial systems and address critical industrial challenges through ingredient and biotics development, process optimisation and product innovation. Combining expertise in strain engineering, microbial metabolism, fermentation and bioprocess development with proprietary technologies and an integrated industrial approach, Abolis supports projects from early discovery through to scale-up readiness and industrial application. Synthetic Biology, Metabolic engineering, Pathway engineering, Molecular biology, Fine chemicals, Performance chemicals, Bioinformatics, nutrition, …

143 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing what’s next in nutrition De Novo Foodlabs is a pioneering biotech start-up revolutionising the field of nutrition. Leveraging the power of microbial fermentation, the company creates innovative products that promote better health for both people and the planet. Food design, Product Development, Recombinant proteins, nutrition, health, and alternativeproteins

188 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Customer precision probiotics at scale. The human microbiome is one of the most important frontiers in modern health science. Changes in the gut microbiome—known as dysbiosis—are increasingly linked to conditions such as IBS, IBD, Crohn’s disease, metabolic disorders, autoimmune disease, and more. Yet despite the growing science, most solutions still rely on generic probiotics that ignore a fundamental reality: every person’s microbiome is unique. Flore is changing that. By combining and advanced informatics and 9+ years of aggregated data, Flore helps individuals understand their unique microbiome signature and delivers precision probiotics tailored to their biology. Our mission is to empower …

63 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Data Analytics

A new way to tackle chronic refractory infections ! Santero Therapeutics is a Belgian biotechnology company developing first-in-class medicines for chronic treatment-refractory infections. Founded in 2021 as a spin-off from the Université Libre de Bruxelles (ULB), the company builds on nearly 20 years of foundational research into the mechanisms governing bacterial survival and persistence. Based in Mont-Saint-Guibert, Belgium, Santero's team of scientists and professionals is advancing a platform of RSH enzyme inhibitors with the potential to transform outcomes for patients living with chronic infections that current treatments cannot resolve. biotechnology , pharma, refractory infection, chronic treatment, and bacteria

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Enhance Quality of Life Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company that develops and commercialises a differentiated portfolio of innovative medicines focusing on indications where existing treatments are inadequate for the target population. It deploys breakthrough technologies to develop medicines that enable patient autonomy, decentralise patient care and provide superior health outcomes. Oral Thin Films, Geriatrics, Paediatrics, Patient autonomy, Equitable Access, Innovative medicines, Medication adherence, Central Nervous System, Women's Health, and Neurology

616 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Smarter antibiotics for a healthier tomorrow. smartbax is a German biotech startup, founded in Munich in 2021, dedicated to developing innovative antibiotics to combat the rising threat of multidrug-resistant bacteria. Our vision is to create smarter antibiotics for a healthier tomorrow. By combining cutting-edge technology with deep scientific expertise, our team designs drugs to outsmart bacterial resistance – addressing one of the most urgent threats to global health. At smartbax, we believe preventing a crisis tomorrow means taking action today. antibiotics

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

630 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

rethinking microbiome Mikrobiomik is a biopharmaceutical company created for the research and development of therapies based on the human microbiome. Our Mission At Mikrobiomik we develop innovative therapies based on intestinal microbiota to offer new therapeutic options in serious diseases with unmet medical needs. Through our FSPIM® technology, we work to restore the balance of the microbiome and provide healthcare professionals and patients with safe, standardized and accessible therapeutic solutions in clinical practice. Fecal microbiota transplant (FMT)

63 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. Our pipeline is both in Human and Veterinary medicine. Our drugs are …

370 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Phico Therapeutics is a biotechnology company advancing the war on antibiotic resistance with engineered phage therapy. At Phico, we are developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”. Our patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. With a number of advantages over conventional antibiotic classes, SASPjectTM could form the basis for a new generation of antibiotics to overcome antimicrobial resistance. Watch our animation to discover how our technology works: https://www.youtube.com/channel/UCjPndK0F9ufmEy9fBQFTsUg Twitter: @Phicotx …

65 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Casting light on the microbiome We founded mbiomics to improve peoples lives by providing a novel approach to fully understand the secrets of the microbiome with the goal to better inform targeted therapies and how to lead a healthy life. microbiome, precision medicine, biotechnology, diagnostics, immuno-oncology, and companion diagnostics

221 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

End-to-end phage company safeguarding human and animal health by harnessing sustainable, antibacterial technology. NexaBiome's patented technology enables bacteriophages to be covalently attached to a wide variety of substrates. This gives them enhanced stability for use in a variety of applications which address two of the world's major challenges: antibiotic resistance and diabetic foot infections. By attaching specific bacteriophages to wound dressings and other substrates, we can reduce, augment or even substitute for antibiotics in human health. This lets us target disease-causing bacteria such as S. aureus, E. coli, Listeria, Campylobacter, Salmonella, Streptococcus, Pseudomonas and others. As our bonded phage products …

56 similar entities Type: Startup Activities: biotech deeptech Technologies: Decarbonization

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

a wholly owned subsidiary of Eli Lilly and Company LimmaTech Biologics AG, a wholly owned subsidiary of Eli Lilly and Company, is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. vaccines, research & development, biotechnology, and antimicrobial resistance

419 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Treating Neurodegenerative Disease by Restoring Autophagy At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families. biotechnology, biopharmaceuticals, rare disease, neurodegeneration, longevity, drug discovery, and drug development

428 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Novel small-molecule drugs in immunology, fibrosis and women health Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting indications with high unmet medical need in immunology, fibrosis and women health. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, Inflammation and autoimmune diseases, IP generation, IBD, Ulcerative Colitis, Crohn's disease, Fibrosis, and Uterine fibroids

346 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering the development of microbiome-based therapies using proprietary tools for their design and production. PharmaBiome is a privately-held spin-off company of ETH Zurich and a pioneer in the production of live biotherapeutic products to address disturbances of the gut microbiome. It has developed the first-in-the-industry, patent-protected technology platform for the production of standardized microbiome-based products. Founded in Zurich in 2015, at the intersection of microbiology, biotechnology, and data science, PharmaBiome believes that the future of microbiome-based therapeutics lies in developing the biotechnology needed to produce a solution compatible with the safety, efficiency, and trial requirements of any human medicine. This …

92 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class solutions for unmet health and personal care needs Results through innovation. We are an innovative biotechnology group with two divisions. Our consumer health arm has commercial products for the personal care market addressing nail, skin, scalp and hair issues. NovaBiotics pharma division has advanced clinical-stage product candidates for medically unmet, life-limiting inflammatory, infectious and respiratory disease. Our highly disruptive solutions to personal care and health needs address significant global markets. biotechnology, biologics, infectious disease, and drug discovery & development

225 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovation for Biotherapies BIOSYNEX was founded in 2005 and is one of the most significant European manufacturers and provider of rapid membrane tests in the in-vitro diagnostic market. By staying close to our customers and business partners we are aware of the needs and expectations they may have of our products and services. Listening to their voice, together with the help of our Research and Development laboratories in France and our state of the art manufacturing facilities, allows us to identify new applications in rapid testing, develop and launch innovative products and provide high quality services. Our aim is to …

297 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

For humanity to thrive, we need transformative thinking in how vaccines and therapeutics are designed and produced. At Univercells, we believe in the power of small adaptations to drive big change. We embrace the spirit of evolution in everything we do. We are biotech innovators. We are scientists and entrepreneurs creating transformative platforms for the pharmaceutical and biotech industry, through technology, bioprocess know-how and entrepreneurial spirit. Biotechnology, mRNA, CDMO, and Services

127 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology

Expert in microbiota and biofilm BioFilm Control is a French biotech company expert in microbiota and biofilm since 2005. We work with R&D laboratories and marketing departments of pharmaceutical, cosmetic, oral care, veterinary, food, hygiene and food supplement industries to help them characterize and optimize the activity of their products on microbiota.

61 similar entities Type: SMB Activities: biotech deeptech

Investing dark biodiversity DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the microbial dark matter. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by DEINOVE (antibiotics, antifungals, antivirals and antiparasitics) target superbugs (microbes that resist to one or several antimicrobials) that cause life-threatening infections which are now spreading at high speed. This breakthrough approach gave birth to one of the World first specialized micro-biotechnology platforms and a unique collection …

72 similar entities Type: SMB Activities: biotech deeptech

Harnessing beneficial bacteria to treat chronic inflammatory skin conditions. MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion WW dermatology and skin care market. We are developing therapies for the top 5 dermatology & skin care conditions - Atopic Dermatitis, Rosacea, Psoriasis, Acne, and Skin Infections, which have a huge impact on quality of life. More than 230 million patients suffer from these 5 skin diseases, which represent a $12.9 Billion Rx market and a $121 Billion skin care market. MatriSys Bio’s scientific approach is to rebalance the natural skin microbiome by application of microbial …

65 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Bio sourced materials

A global leader in life sciences. Advancing quality, innovation, and confidence in results. Nova Biomedical is entering a new chapter. Advanced Instruments and Nova Biomedical have united to form a larger, more focused global life science tools company operating under the Nova Biomedical name. By bringing together two innovation‐driven organizations, we have expanded our capabilities across bioprocessing and clinical diagnostics, strengthening how we serve customers and accelerating our impact across life sciences. Today’s Nova Biomedical is a global leader in supporting bioprocessing workflows and in vitro diagnostics (IVD), guided by a renewed leadership team, sharper priorities, and a clear focus …

247 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Mission We harness the power of molecular microbiology to develop diagnostic solutions that will optimize the treatment of life-threatening, drug resistant infections. We seek to dramatically transform patient care to guide antibiotic therapy selection and help improve antibiotic stewardship. About Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics to help combat infectious disease. Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels to address the global threat of antimicrobial resistance (AMR), improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs). Together we improve patient …

67 similar entities Type: SMB Activities: biotech deeptech Technologies: A.I. Synthetic Biology

We are unyielding in our pursuit of life-changing therapies and our grit and compassion lead us to fight for a better future for patients and their families. We believe there is tremendous potential in the area of targeting the immune system through the gut microbiome. By working with the microbiome rather than replacing it, Kaleido is in a unique position to unlock an untapped area of science with unprecedented new treatments.

57 similar entities Type: Startup Activities: biotech deeptech

At Bioharmony Therapeutics, we are developing nontraditional antimicrobial therapeutics by exploiting millions of years of phage-bacteria evolution. Our focus is on targeting infectious diseases caused by multidrug-resistant (MDR) Gram-negative bacteria. Our primary therapeutic indication is for Acinetobacter baumannii skin and wound infections.

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We develop solutions to expensive and life-threatening infections in both the medical and food industries. At Detact We Believe That Bacterial Detection Is Vital To Sustain Healthy Living. Preventing Bacterial Contamination Is Key. We Produce Bacterial Detection Solutions, Reliable, Affordable, Easy And Fast.

49 similar entities Type: Startup Activities: deeptech

Formulating the Future of BiologicsTM Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, HyperconTM, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are …

276 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reshaping the future of crop protection and biotechnological production - Growth Without Compromise At SenseUP, we develop precision RNA solutions for sustainable plant protection and animal health that are effective, affordable and residue-free. As a spin-off of the renowned German Institute for Biotechnology at Forschungszentrum Jülich (FZJ), we have a strong foundation in scientific excellence. With our deep expertise and patented technologies, we utilise a Corynebacterium-based fermentative platform for the affordable and scalable production of encapsulated dsRNA. This active ingredient protects crops against insects, nematodes, fungi. Microbial strain-development, Fluorescence activated cell-sorting, Fermentation, High-throughput screening, RNA, dsRNA, Bioinsecticides, Biofungicides, Biopesticides, #sustainability …

147 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

From complexity to clarity in the microbiome Accelerate and transform discovery research and capitalize on the diverse opportunities of the microbiome with Diversigen. Diversigen provides comprehensive fee-for-service microbiome and metagenomics services focused on solutions to improve human, animal, and environmental health. Diversigen is at the forefront of setting industry standards for quality with a microbiome CLIA/CAP accredited, GLP compliant laboratory. Diversigen has extensive experience with highly diverse microbiome sample types and provides full project life cycle consulting services, building on research conducted at Baylor College of Medicine in the Alkek Center for Metagenomics and Microbiome Research. From pre-project consulting, study …

53 similar entities Type: Startup Activities: deeptech biotech Technologies: Data Analytics

BaseClear offers genomics expertise and consultancy to accelerate the understanding and use of microorganisms. Microbes have a huge potential to contribute to the solution of a large number of issues facing the modern world, ranging from antibiotic resistance and personal disease to poor crop yields and problems caused by global warming. For years, relatively little was known about the often-invisible world of microbes. However, the latest DNA technologies have provided tools to really see what is happening inside microbes and within microbial communities. This allow us to unravel the interactions between microbes and their hosts and environment. BaseClear, founded in …

73 similar entities Type: SMB Activities: biotech deeptech